NICE Guidelines Set to Reduce Unnecessary Colonoscopies

By Staff Writer

September 21, 2023

A New Era for Colorectal Cancer Diagnosis

The National Institute for Health and Care Excellence (NICE) has released new guidance that could spare tens of thousands of people the need for a colonoscopy each year. The updated guidelines recommend offering people with signs or symptoms of colorectal cancer a home test using quantitative faecal immunochemical tests (FIT).

These tests, which measure the amount of blood in the faeces, could lead to faster diagnoses and fewer referrals to secondary care for unnecessary colonoscopies. This shift in approach would allow colonoscopy services to focus on the patients who need them most, improving both patient care and healthcare efficiency.

Positive Impact on the NHS and Patient Care

The North Tees and Hartlepool NHS Foundation Trust has already implemented the approach recommended by NICE. They found that they detected more cancers using fewer colonoscopies, which is beneficial for both patients and the NHS.

Mark Chapman, interim director of medical technology and digital evaluation at NICE, said the new recommendations could help around 100,000 people avoid unnecessary colonoscopies. Furthermore, it will free up waiting lists to diagnose those more likely to have colorectal cancer.

Genevieve Edwards, chief executive at Bowel Cancer UK, added that the new guidance would help GPs identify and refer the right patients for further testing quickly, potentially detecting bowel cancer at an earlier stage when it is more treatable and curable.

With colorectal cancer being the fourth most common cancer in the UK, these new guidelines represent a significant step forward in managing its diagnosis and treatment.

Reference url

Recent Posts

FDA Guidance on Overall Survival Assessment in Oncology Trials

By Staff Writer

August 20, 2025

Overall survival assessment serves as the gold standard for determining the true impact of oncology treatments, directly answering patient and provider questions such as: “How will this therapy affect my length of life?” According to the latest FDA guidance, robust overall survival assessment is ...
Guiding the Future of Digital Cardiac Rehabilitation: NICE’s Conditional Recommendations
The National Institute for Health and Care Excellence (NICE) has issued consultative draft guidance recommending six digital cardiac rehabilitation technologies for adults with cardiovascular disease (CVD). These technologies are conditionally recommended for use in the NHS during a three-year ev...
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit

By João L. Carapinha

August 19, 2025

A recent G-BA decision provides a systematic evaluation of Glofitamab Gemcitabine DLBCL, combined with Gemcitabine and Oxaliplatin (GemOx), for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. The review...